UROLOGY / BASIC RESEARCH
Association between inflammatory cytokines and prostate cancer: a bidirectional Mendelian randomization study
More details
Hide details
1
Ningbo Medical Centre LiHuiLi Hospital, China
2
Xiuzhou District People’s Hospital of Jiaxing, China
Submission date: 2024-03-02
Final revision date: 2024-07-01
Acceptance date: 2024-07-04
Online publication date: 2024-07-28
Corresponding author
Lin Cao
Xiuzhou District
People’s Hospital
of Jiaxing,
China
Arch Med Sci 2025;21(5):2102-2112
KEYWORDS
TOPICS
ABSTRACT
Introduction:
We conducted a bidirectional two-sample Mendelian randomization (MR) analysis to investigate the causal relationship between 91 inflammatory cytokines and prostate cancer (PCa).
Material and methods:
The inverse variance weighted (IVW) model served as the primary two-sample MR analysis method, utilized to estimate the causal effect of exposure on the outcome. The weighted median (WM) and MR Egger methods were additionally employed to complement the IVW model. Sensitivity analyses were performed using Cochran’s Q test for both the IVW and MR Egger methods. To assess the presence of horizontal pleiotropy, the instrumental variables (IVs) were subjected to the MR-Egger intercept test.
Results:
Following Bonferroni correction, the IVW analysis revealed positive correlations between PCa and the levels of C-C motif chemokine 20 (CCL20), C-C motif chemokine 23 (CCL23), fibroblast growth factor 19 (FGF19), fibroblast growth factor 23 (FGF23), and interleukin-6 (IL-6). Notably, IL-6 exhibited the strongest positive association effect (odds ratio [95% confidence interval]: 1.0076 [1.0014, 1.0139]), followed by CCL-20 (1.0067 [1.0004, 1.0129]) and FGF23 (1.0002, 1.0119). Reverse MR analysis indicated a negative causal relationship between PCa and interleukin-22 receptor subunit alpha-1 levels (IL22RA1) (0.4852 [0.2390, 0.9847]).
Conclusions:
This study suggested that there is a positive correlation between the levels of CCL20, CCL23, FGF19, FGF23, and IL-6 and the occurrence of PCa. Furthermore, we found evidence to support the causal relationship between decreased levels of IL22RA1 and the development of PCa. These findings reveal novel biomarkers and pathways that could potentially be targeted for the prevention and clinical treatment of PCa.
REFERENCES (25)
1.
James ND, Tannock I, N’Dow J, et al. The Lancet Commission on prostate cancer: planning for the surge in cases. Lancet 2024; 403: 1683-722.
2.
Withrow D, Pilleron S, Nikita N, et al. Current and projected number of years of life lost due to prostate cancer: a global study. Prostate 2022; 82: 1088-97.
3.
Talkar SS, Patravale VB. Gene therapy for prostate cancer: a review. Endocrine Metab Immune Disord Drug Targets 2021; 21: 385-96.
4.
Miyahira AK, Soule HR. The 28th Annual Prostate Cancer Foundation Scientific Retreat report. Prostate 2022; 82: 1346-77.
5.
Sekhoacha M, Riet K, Motloung P, et al. Prostate cancer review: genetics, diagnosis, treatment options, and alternative approaches. Molecules 2022; 27: 5730.
6.
Rebbeck TR. Prostate cancer genetics: variation by race, ethnicity, and geography. Semin Radiat Oncol 2017; 27: 3-10.
7.
Haller H, Bertram A, Nadrowitz F, et al. Monocyte chemoattractant protein-1 and the kidney. Curr Opin Nephrol Hypertens 2016; 25: 42-9.
8.
Zeitoun T, El-Sohemy A. Using Mendelian randomization to study the role of iron in health and disease. Int J Mol Sci 2023; 24: 13458.
9.
Bowden J, Holmes MV. Meta-analysis and Mendelian randomization: a review. Res Synthesis Methods 2019; 10: 486-96.
10.
Birney E. Mendelian randomization. Cold Spring Harbor Perspect Med 2022; 12: a041302.
11.
Burgess S, Thompson SG. Interpreting findings from Mendelian randomization using the MR-Egger method. Eur J Epidemiol 2017; 32: 377-89.
12.
Ference BA. Interpreting the clinical implications of drug-target mendelian randomization studies. J Am Coll Cardiol 2022; 80: 663-5.
13.
Larsson SC, Butterworth AS, Burgess S. Mendelian randomization for cardiovascular diseases: principles and applications. Eur Heart J 2023; 44: 4913-24.
14.
Jang KS, Han IH, Lee SJ, et al. Experimental rat prostatitis caused by Trichomonas vaginalis infection. Prostate 2019; 79: 379-89.
15.
Konkol Y, Vuorikoski H, Streng T, et al. Characterization a model of prostatic diseases and obstructive voiding induced by sex hormone imbalance in the Wistar and Noble rats. Transl Androl Urol 2019; 8 (Suppl 1): S45-57.
16.
Wang L, Zoetemelk M, Chitteti BR, et al. Expansion of prostate epithelial progenitor cells after inflammation of the mouse prostate. Am J Physiol Renal Physiol 2015; 308: F1421-30.
17.
Nagamatsu H, Teishima J, Goto K, et al. FGF19 promotes progression of prostate cancer. Prostate 2015; 75: 1092-101.
18.
Guo J, Liang Y, Xue D, et al. Tumor-conditional IL-15 pro-cytokine reactivates anti-tumor immunity with limited toxicity. Cell Res 2021; 31: 1190-8.
19.
Hirsch V, Wolgin M, Mitronin AV, et al. Inflammatory cytokines in normal and irreversibly inflamed pulps: a systematic review. Arch Oral Biol 2017; 82: 38-46.
20.
Feng S, Wang J, Zhang Y, et al. FGF23 promotes prostate cancer progression. Oncotarget 2015; 6: 17291-301.
21.
Andoh A, Nishida A. Pro- and anti-inflammatory roles of interleukin (IL)-33, IL-36, and IL-38 in inflammatory bowel disease. J Gastroenterol 2023; 58: 69-78.
22.
Adamo L, Rocha-Resende C, Prabhu SD, et al. Reappraising the role of inflammation in heart failure. Nat Rev Cardiol 2020; 17: 269-85.
23.
Bennett JL, Jackson BN, Miller RJ, et al. IL-6 evoked biochemical changes in prostate cancer cells. Cytokine 2023; 161: 156079.
24.
Stark T, Livas L, Kyprianou N. Inflammation in prostate cancer progression and therapeutic targeting. Transl Androl Urol 2015; 4: 455-63.
25.
Perez-Cornago A, Appleby P N, Pischon T, et al. Tall height and obesity are associated with an increased risk of aggressive prostate cancer: results from the EPIC cohort study. BMC Med 2017; 15: 115.